Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Kern Sliwa

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Early Intervention in Psychiatry|January 28, 2016
Re: Review article titled 'Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia' (Stevens GL et al. Early Interv Psychiatry 2015 Sep 25. doi: 10.1111/eip.12278)Larry Alphs, Cynthia Bossie, Jennifer Kern Sliwa
Journal of Psychosocial Nursing and Mental Health Services|November 1, 2019
Long-Acting Injectable AntipsychoticsKaren Johnston, Jennifer Kern Sliwa, Cynthia A Bossie, et al.
Schizophrenia Research|July 22, 2011
Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidoneJennifer Kern Sliwa, Cynthia A Bossie, Yi-Wen Ma, et al.
CNS Spectrums|December 28, 2018
Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychoticsChristoph U Correll, Jennifer Kern Sliwa, Dean M Najarian, et al.
BMC Psychiatry|February 25, 2014
Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitateJennifer Kern Sliwa, Dong-Jing Fu, Cynthia A Bossie, et al.
Neuropsychiatric Disease and Treatment|September 8, 2012
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophreniaJennifer Kern Sliwa, Cynthia A Bossie, Dong-Jing Fu, et al.
Clinical Schizophrenia & Related Psychoses|March 1, 2013
Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimensDong-Jing Fu, Cynthia A Bossie, Jennifer Kern Sliwa, et al.
Expert Opinion on Pharmacotherapy|April 24, 2014
Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophreniaLarry Alphs, Cynthia A Bossie, Dong-Jing Fu, et al.
Neuropsychiatric Disease and Treatment|June 1, 2013
Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed doseMahesh N Samtani, Isaac Nuamah, Srihari Gopal, et al.
Therapeutic Advances in Psychopharmacology|August 29, 2013
Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trialCynthia A Bossie, Dong-Jing Fu, Jennifer Kern Sliwa, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Early Intervention in Psychiatry|January 28, 2016
Re: Review article titled 'Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia' (Stevens GL et al. Early Interv Psychiatry 2015 Sep 25. doi: 10.1111/eip.12278)Larry Alphs, Cynthia Bossie, Jennifer Kern Sliwa
Journal of Psychosocial Nursing and Mental Health Services|November 1, 2019
Long-Acting Injectable AntipsychoticsKaren Johnston, Jennifer Kern Sliwa, Cynthia A Bossie, et al.
Schizophrenia Research|July 22, 2011
Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidoneJennifer Kern Sliwa, Cynthia A Bossie, Yi-Wen Ma, et al.
CNS Spectrums|December 28, 2018
Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychoticsChristoph U Correll, Jennifer Kern Sliwa, Dean M Najarian, et al.
BMC Psychiatry|February 25, 2014
Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitateJennifer Kern Sliwa, Dong-Jing Fu, Cynthia A Bossie, et al.
Neuropsychiatric Disease and Treatment|September 8, 2012
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophreniaJennifer Kern Sliwa, Cynthia A Bossie, Dong-Jing Fu, et al.
Clinical Schizophrenia & Related Psychoses|March 1, 2013
Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimensDong-Jing Fu, Cynthia A Bossie, Jennifer Kern Sliwa, et al.
Expert Opinion on Pharmacotherapy|April 24, 2014
Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophreniaLarry Alphs, Cynthia A Bossie, Dong-Jing Fu, et al.
Neuropsychiatric Disease and Treatment|June 1, 2013
Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed doseMahesh N Samtani, Isaac Nuamah, Srihari Gopal, et al.
Therapeutic Advances in Psychopharmacology|August 29, 2013
Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trialCynthia A Bossie, Dong-Jing Fu, Jennifer Kern Sliwa, et al.
Pageof 3